Adenosine A2A receptors in secondary progressive multiple sclerosis: A [ 11 C]TMSX brain PET study

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 9, 2013, Pages 1394-1401

  Rissanen, Eero ^a   Virta, Jere R ^a   Paavilainen, Teemu ^a   Tuisku, Jouni ^a   Helin, Semi ^a   Luoto, Pauliina ^a   Parkkola, Riitta ^a   Rinne, Juha O ^a   Airas, Laura ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

A2A receptor; adenosine; DTI; multiple sclerosis; PET

Indexed keywords

[(7 N METHYL 11 C) 8 (3,4, 5 TRIMETHOXYSTYRYL) 1,3,7 TRIMETHYLXANTHINE]; ADENOSINE A2A RECEPTOR; CARBON 11; GADOLINIUM; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN SIZE; CEREBELLUM CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS CALLOSUM; CORPUS STRIATUM; DIFFUSION TENSOR IMAGING; DISABILITY; DISEASE DURATION; ENCEPHALITIS; EXPANDED DISABILITY STATUS SCALE; FEMALE; FRACTIONAL ANISOTROPY; FRONTAL CORTEX; GRAY MATTER; HUMAN; IN VIVO STUDY; MALE; MULTIPLE SCLEROSIS; NEOCORTEX; NERVE CELL LESION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITAL CORTEX; PANIC; PARIETAL CORTEX; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PYRAMIDAL TRACT; RADIOACTIVITY; SINUS VENOSUS; SUPERIOR SAGITTAL SINUS; TEMPORAL CORTEX; THALAMUS; WHITE MATTER;

ADULT; AGED; CEREBRAL CORTEX; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A2A;

EID: 84883740885     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.85     Document Type: Article

References (39)

1. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8: 647-656.
2. Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, Barkhof F et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008; 7: 615-625.
3. Moll NM, Rietsch AM, Thomas S, Ransohoff AJ, Lee JC, Fox R et al. Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol 2011; 70: 764-773.
4. Blackburn MR, Vance CO, Morschl E, Wilson CN. Adenosine receptors and inflammation. Handb Exp Pharmacol 2009; 215-269.
5. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414: 916-920. (Pubitemid 34024743)
6. Garcia GE, Truong LD, Li P, Zhang P, Du J, Chen JF et al. Adenosine A2A receptor activation and macrophage-mediated experimental glomerulonephritis. FASEB J 2008; 22: 445-454. (Pubitemid 351225581)
7. Ishiwata K, Wang WF, Kimura Y, Kawamura K, Ishii K. Preclinical studies on [11C]TMSX for mapping adenosine A2A receptors by positron emission tomography. Ann Nucl Med 2003; 17: 205-211. (Pubitemid 36834432)
8. Mishina M, Ishiwata K, Kimura Y, Naganawa M, Oda K, Kobayashi S et al. Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [11C]TMSX PET. Synapse 2007; 61: 778-784. (Pubitemid 47122751)
9. Mishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M et al. Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. PLoS One 2011; 6: e17338.
10. Kulisevsky J, Poyurovsky M. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders. Eur Neurol 2012; 67: 4-11.
11. Naganawa M, Kimura Y, Mishina M, Manabe Y, Chihara K, Oda K et al. Quantification of adenosine A2A receptors in the human brain using [11C]TMSX and positron emission tomography. Eur J Nucl Med Mol Imaging 2007; 34: 679-687. (Pubitemid 46669363)
12. Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011; 76: 1811-1816.
13. Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med 2007; 48: 158-167. (Pubitemid 47555390)
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452. (Pubitemid 14237132)
15. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231. (Pubitemid 13158528)
16. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58: 840-846. (Pubitemid 41746873)
17. Virta JR, Laatu S, Parkkola R, Oikonen V, Rinne JO, Ruutiainen J. Cerebral acetylcholinesterase activity is not decreased in MS patients with cognitive impairment. Mult Scler 2011; 17: 931-938.
18. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004; 23(Suppl 1): S208-S219. (Pubitemid 39421720)
19. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp 2002; 17: 143-155. (Pubitemid 35253488)
20. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006; 31: 1487-1505.
21. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479-489.
22. Gaser C. Structural Brain Mapping Group: 2012 VBM8. http://dbm.neuro. uni-jena.de/vbm/.
23. Wellcome Trust Center for Neuroimaging: 2012 Statistical Parametric Mapping, SPM8. http://www.fil.ion.ucl.ac.uk/spm.
24. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001; 14: 21-36. (Pubitemid 32552740)
25. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007; 38: 95-113. (Pubitemid 47440133)
26. Kawamura K, Ishiwata K. Improved synthesis of [11C]SA4503, [11C]MPDX and [11C]TMSX by use of [11C]methyl triflate. Ann Nucl Med 2004; 18: 165-168. (Pubitemid 38856013)
27. Heiss WD, Habedank B, Klein JC, Herholz K, Wienhard K, Lenox M et al. Metabolic rates in small brain nuclei determined by high-resolution PET. J Nucl Med 2004; 45: 1811-1815. (Pubitemid 47618436)
28. Montgomery AJ, Asselin MC, Farde L, Grasby PM. Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11C]FLB 457 PET. J Cereb Blood Flow Metab 2007; 27: 369-377. (Pubitemid 46148463)
29. Alakurtti K, Aalto S, Johansson JJ, Någren K, Tuokkola T, Oikonen V et al. Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography. J Cereb Blood Flow Metab 2011; 31: 155-165.
30. Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, Frackowiak RS. The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab 1990; 10: 458-466. (Pubitemid 20209192)
31. Okazawa H, Leyton M, Benkelfat C, Mzengeza S, Diksic M. Statistical mapping analysis of serotonin synthesis images generated in healthy volunteers using positron-emission tomography and alpha-[11C]methyl-L-tryptophan. J Psychiatry Neurosci 2000; 25: 359-370.
32. Ciccarelli O, Werring DJ, Barker GJ, Griffin CM, Wheeler-Kingshott CA, Miller DH et al. A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging-evidence of Wallerian degeneration. J Neurol 2003; 250: 287-292. (Pubitemid 36399267)
33. Sebastião AM, Ribeiro JA. Adenosine receptors and the central nervous system. Handb Exp Pharmacol 2009; 193: 471-534.
34. Svenningsson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 1997; 27: 322-335. (Pubitemid 27479470)
35. Färber K, Kettenmann H. Purinergic signaling and microglia. Pflugers Arch 2006; 452: 615-621. (Pubitemid 44015096)
36. Orr AG, Orr AL, Li XJ, Gross RE, Traynelis SF. Adenosine A(2A) receptor mediates microglial process retraction. Nat Neurosci 2009; 12: 872-878.
37. Saura J, Angulo E, Ejarque A, Casadó V, Tusell JM, Moratalla R et al. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem 2005; 95: 919-929. (Pubitemid 41713478)
38. Rebola N, Simõ es AP, Canas PM, Tomé AR, Andrade GM, Barry CE et al. Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J Neurochem 2011; 117: 100-111.
39. Stevens B, Porta S, Haak LL, Gallo V, Fields RD. Adenosine: a neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron 2002; 36: 855-868. (Pubitemid 35447857)